Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study

Next Previous
Trial Profile

LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lysergide (Primary)
  • Indications Anxiety disorders
  • Focus Therapeutic Use
  • Acronyms LSD-Assist Study

Most Recent Events

  • 13 May 2024 According to a Swiss Medical Society for Psycholytic Therapy (SAPT), updated results and long-term data presented at the Society of Biological Psychiatry (SOBP) Meeting in Austin, Texas, original study recognized by SOBP with Somerfeld-Ziskind award for outstanding research investigations in Biological Psychiatry.
  • 13 May 2024 According to a Swiss Medical Society for Psycholytic Therapy (SAPT), announces data demonstrating reductions in anxiety that persist through two years after treatment with LSD after the end of 50 weeks. The LSD-Assist Study conducted in collaboration by investigators from University Hospital Basel (UHB) and APT.
  • 08 Jan 2024 According to a MindMed media release, One-year follow-up data from a Phase 2 placebo-controlled investigator-initiated clinical trial of lysergide in the treatment of anxiety disorders is anticipated in 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top